Breast Cancer
News
ASRM: Egg Freezing No Longer 'Experimental'
News
Can Lapatinib Prevent Brain Metastases from Breast Cancer? Data 'Inconclusive'
Major Findings: The primary end point of CNS as first site of relapse was no different comparing lapatinib-capecitabine (3%) vs. trastuzumab-...
News
TURANDOT Revisits Bevacizumab Partners in Metastatic Breast Cancer
Major Finding: Secondary end points of progression-free survival (HR 1.36, P = .005) and objective response rates (P less than .0001) were...
News
Baseline Factors Trump Response to Therapy in Mastectomy Decisions
Major Findings: Half of all patients treated with a dual HER2 blockade and paclitaxel achieved a pathological complete response, but 58.6% went on...
News
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
News
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
News
Another Study Finds No Glargine, Breast Cancer Link
Major Finding: The rate of breast cancer among women who received insulin glargine was similar to that of women who had not received glargine.Data...
News
EMILIA Confirms T-DM1 Overall Survival Advantage
Major Finding: Median overall survival was 30.9 months for T-DM1 and 25.1 months for capecitabine plus lapatinib (hazard ratio = 0.68, P = .0006)....
News
One Year of Trastuzumab Remains the Standard in Early Breast Cancer
Major Findings: The hazard ratios for disease-free and overall survival comparing 1 year and 2 years of adjuvant trastuzumab in the HERA trial...